Incyte Will File Jakafi For Acute GVHD In US Based On Phase II Success
The JAK1/2 inhibitor may add an indication for acute graft-versus-host disease, though based on a single, open-label Phase II trial that showed a 55% response rate in a high-mortality indication.
You may also be interested in...
Incyte's hopes of reducing its reliance on Jakafi have suffered a blow after a Phase III trial of itacitinib failed. The stock has slumped and analysts are raising concerns about the company's ability to generate value from its hefty R&D investments.
The Dutch biotech's CEO tells Scrip that one-week treatment with T-Guard could change the paradigm for tackling steroid-refractory graft-versus-host disease.
Keeping Track: Novartis Scores Big Ahead Of US Memorial Day With Approvals For Gene Therapy Zolgensma, Oncologic Piqray
The latest drug development news and highlights from our US FDA Performance Tracker.